Can both plants and humans benefit from new cross-cutting research between experts in pharmaceuticals and agriculture? Bayer is betting that the answer is “yes” and announced a new joint venture on Tuesday with Arvinas, a pioneer in Proteolysis-Targeting Chimera, also known as PROTACs. PROTAC® technology harnesses the naturally occurring protein degradation system of the cell to selectively remove target proteins by proteolysis, the breakdown of proteins into amino acids. Because the technology degrades targets rather than inhibiting them, it offers a completely new category of crop protection applications in agriculture, according to Bayer. In addition, the firm says PROTACs have the potential to revive crop protection mechanisms that have become ineffective due to resistance. “The goal is to utilize the complementary expertise of Bayer and Arvinas to develop novel research discoveries that ultimately deliver new crop protection products for farmers,” said Dr. Robert Reiter, Member of the Executive Committee of Bayer AG's Crop Science Division and Head of Crop Science Research & Development. In addition, Bayer plans to collaborate with Arvinas to develop next-generation medicines for patients with cardiovascular, oncological and gynecological diseases leveraging PROTAC technology. In late May, the firm’s lead PROTAC protein degrader was granted Fast Track designation by the Food and Drug Administration for the treatment of men with certain types of prostate cancer.

For more news go to: